28168163|t|Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer
28168163|a|We determined factors associated with morbidity and outcomes of a series of non-small cell lung cancer (NSCLC) patients treated with dose-escalated chemoradiotherapy at the University of Pittsburgh Lung Cancer Program. The records of 170 stage III NSCLC patients treated with definitive intent were retrospectively reviewed. All patients received four-dimensional CT simulation scan and had respiratory gating if tumor movement exceeded 5 mm. Overall survival (OS), locoregional control (LRC), and freedom from distant metastasis (FFDM) were calculated using log-rank and Cox regression analysis. For the present series of patients, median follow-up was 36.6 months, median survival 27.4 months, and the 2- and 4- year OS was 56.0 and 30.7%, respectively. The 4- year LRC and FFDM were 43.9 and 40.7%, respectively. No benefit was associated with irradiation doses above 66 Gy in OS (p = 0.586), LRC (p = 0.440), or FFDM (p = 0.230). On univariate analysis, variables associated with worse survival included: clinical stage IIIB (p = 0.037), planning target volume (PTV) over 450 cc (p < 0.001), heart V30 over 40% (p = -0.048), and esophageal mean dose over 20% (p = 0.024), V5 (p = -0.015), and V60 (p = -0.011). On multivariable analysis, PTV above 450 cc (52.2 vs. 25.3 months, p < 0.001) and esophageal V60 >20% (43.8 vs. 21.3 months, p = -0.01) were associated with lower survival. Grade 2 or higher acute lung toxicity and esophagitis were detected in 9.5 and 59.7%, respectively of patients. Grade 2 or higher acute lung toxicity was reduced if lung V5 was ≤65 (7.4 vs. 23.8%, p = 0.03). Grade 2 or higher acute esophagitis was reduced if V60 ≤ 20% (62 vs. 81.3%, p = 0.018). The use of intensity-modulated radiation therapy was more frequent in stage IIIB compared to stage IIIA patients (56.5 vs. 39.5%, p = 0.048) and was associated with a higher lung V5 and V10. The outcomes of a program of dose-escalated chemoradiotherapy for unresectable stage IIIA and IIIB NSCLC patients were consistent with other studies and showed no benefit to radiation doses above 66 Gy. Furthermore, maintaining low esophageal V60 and lung V5 were associated with lower morbidity and mortality.
28168163	0	7	Results	T169	C1274040
28168163	13	19	Single	T081	C0205171
28168163	20	31	Institution	T169	C0205245
28168163	32	42	Experience	T078	C1254370
28168163	48	62	Dose-Escalated	T169	C3816728
28168163	63	77	Chemoradiation	T061	C0436307
28168163	82	89	Locally	T082	C0205276
28168163	90	98	Advanced	T080	C0205179
28168163	99	111	Unresectable	T201	C1519810
28168163	112	138	Non-Small Cell Lung Cancer	T191	C0007131
28168163	153	160	factors	T169	C1521761
28168163	161	176	associated with	T080	C0332281
28168163	177	186	morbidity	T081	C0026538
28168163	191	199	outcomes	T169	C1274040
28168163	215	241	non-small cell lung cancer	T191	C0007131
28168163	243	248	NSCLC	T191	C0007131
28168163	250	258	patients	T101	C0030705
28168163	259	266	treated	T061	C0087111
28168163	272	286	dose-escalated	T169	C3816728
28168163	287	304	chemoradiotherapy	T061	C0436307
28168163	312	356	University of Pittsburgh Lung Cancer Program	T058	C0679841
28168163	362	369	records	T170	C0034869
28168163	377	392	stage III NSCLC	T191	C0278506
28168163	393	401	patients	T101	C0030705
28168163	402	409	treated	T061	C0087111
28168163	438	462	retrospectively reviewed	T062	C0035363
28168163	468	476	patients	T101	C0030705
28168163	486	521	four-dimensional CT simulation scan	T060	C2717955
28168163	530	548	respiratory gating	T074	C3877328
28168163	552	557	tumor	T191	C0027651
28168163	558	566	movement	T040	C0026649
28168163	582	598	Overall survival	T081	C4086681
28168163	600	602	OS	T081	C4086681
28168163	605	617	locoregional	T191	C0027643
28168163	618	625	control	T080	C0243148
28168163	627	630	LRC	T080	C0243148
28168163	637	668	freedom from distant metastasis	T043	C1513178
28168163	670	674	FFDM	T043	C1513178
28168163	698	706	log-rank	T170	C0392366
28168163	711	734	Cox regression analysis	T170	C0034980
28168163	762	770	patients	T101	C0030705
28168163	779	788	follow-up	T058	C1522577
28168163	798	804	months	T079	C0439231
28168163	806	821	median survival	T079	C2986586
28168163	827	833	months	T079	C0439231
28168163	853	857	year	T079	C0439234
28168163	858	860	OS	T081	C4086681
28168163	902	906	year	T079	C0439234
28168163	907	910	LRC	T080	C0243148
28168163	915	919	FFDM	T043	C1513178
28168163	970	985	associated with	T080	C0332281
28168163	986	1003	irradiation doses	T061	C2169144
28168163	1013	1015	Gy	T081	C0556636
28168163	1019	1021	OS	T081	C4086681
28168163	1035	1038	LRC	T080	C0243148
28168163	1055	1059	FFDM	T043	C1513178
28168163	1076	1095	univariate analysis	T062	C0683962
28168163	1097	1106	variables	T080	C0439828
28168163	1107	1122	associated with	T080	C0332281
28168163	1123	1128	worse	T033	C1457868
28168163	1129	1137	survival	T169	C0220921
28168163	1148	1156	clinical	T080	C0205210
28168163	1157	1167	stage IIIB	T191	C0278984
28168163	1181	1203	planning target volume	T081	C0454199
28168163	1205	1208	PTV	T081	C0454199
28168163	1235	1240	heart	T023	C0018787
28168163	1272	1282	esophageal	T082	C1522619
28168163	1288	1292	dose	T081	C4019308
28168163	1357	1379	multivariable analysis	T081	C0026777
28168163	1381	1384	PTV	T081	C0454199
28168163	1413	1419	months	T079	C0439231
28168163	1436	1446	esophageal	T082	C1522619
28168163	1471	1477	months	T079	C0439231
28168163	1495	1510	associated with	T080	C0332281
28168163	1511	1516	lower	T080	C0205556
28168163	1517	1525	survival	T169	C0220921
28168163	1527	1534	Grade 2	T185	C0475270
28168163	1538	1544	higher	T080	C0205250
28168163	1545	1550	acute	T079	C0205178
28168163	1551	1555	lung	T023	C0024109
28168163	1556	1564	toxicity	T080	C0040539
28168163	1569	1580	esophagitis	T047	C0014868
28168163	1586	1594	detected	T033	C0442726
28168163	1629	1637	patients	T101	C0030705
28168163	1639	1646	Grade 2	T185	C0475270
28168163	1650	1656	higher	T080	C0205250
28168163	1657	1662	acute	T079	C0205178
28168163	1663	1667	lung	T023	C0024109
28168163	1668	1676	toxicity	T080	C0040539
28168163	1681	1688	reduced	T080	C0392756
28168163	1692	1696	lung	T023	C0024109
28168163	1735	1742	Grade 2	T185	C0475270
28168163	1746	1752	higher	T080	C0205250
28168163	1753	1758	acute	T079	C0205178
28168163	1759	1770	esophagitis	T047	C0014868
28168163	1775	1782	reduced	T080	C0392756
28168163	1834	1871	intensity-modulated radiation therapy	T061	C1512814
28168163	1881	1889	frequent	T079	C0332183
28168163	1893	1903	stage IIIB	T191	C0278984
28168163	1916	1926	stage IIIA	T191	C0278983
28168163	1927	1935	patients	T101	C0030705
28168163	1972	1987	associated with	T080	C0332281
28168163	1990	1996	higher	T080	C0205250
28168163	1997	2001	lung	T023	C0024109
28168163	2018	2026	outcomes	T169	C1274040
28168163	2032	2039	program	T058	C0679841
28168163	2043	2057	dose-escalated	T169	C3816728
28168163	2058	2075	chemoradiotherapy	T061	C0436307
28168163	2080	2092	unresectable	T201	C1519810
28168163	2093	2103	stage IIIA	T191	C0278983
28168163	2108	2112	IIIB	T191	C0278984
28168163	2113	2118	NSCLC	T191	C0007131
28168163	2119	2127	patients	T101	C0030705
28168163	2133	2148	consistent with	T078	C0332290
28168163	2155	2162	studies	T062	C2603343
28168163	2188	2203	radiation doses	T081	C4019308
28168163	2213	2215	Gy	T081	C0556636
28168163	2246	2256	esophageal	T082	C1522619
28168163	2265	2269	lung	T023	C0024109
28168163	2278	2293	associated with	T080	C0332281
28168163	2300	2309	morbidity	T081	C0026538
28168163	2314	2323	mortality	T081	C1516192